Alto Neuroscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
Alto Neuroscience, Inc. (ANRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations of 157.37 thousand shares for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations · last filed 2025-11-12
- Alto Neuroscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2025-09-30 was 0.00 shares.
- Alto Neuroscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2025-06-30 was 0.00 shares.
- Alto Neuroscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2025-03-31 was 157.37K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 9 month |
|---|---|---|---|
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-12 | 157.37K shares 10-Q · filed 2025-11-12 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 157.37K shares 10-Q · filed 2025-08-13 | |
| 2025-03-31 | 157.37K shares 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |